1. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review
- Author
-
Christine Do Cao, Sophie Leboulleux, A. Alghuzlan, Laurence Leenhardt, Yann Godbert, Slimane Zerdoud, Françoise Borson Chazot, Isabelle Borget, Christelle De La Fouchardiere, Stéphane Bardet, Centre Léon Bérard [Lyon], Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Institut E3M [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) more...
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Thyroid carcinoma ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Target therapy ,Medical treatment ,business.industry ,Thyroid ,Antiangiogenic therapy ,Treatment options ,Hematology ,General Medicine ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business - Abstract
Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of cancer-related death. Multidisciplinary discussions can assess the role and the nature of local treatments, but also determine the optimal timing for first-line antiangiogenic therapy as some of these patients can be followed for several months or years without any treatment. In this review, we will examine the definition of RAIR-DTC, the different treatment options and finally some of the most recent cancer research breakthroughs for RAIR-DTC. more...
- Published
- 2019
- Full Text
- View/download PDF